Icosavax, Inc.
ICVXNASDAQHealthcare
$15.31
$-0.14(-0.91%)
Market Cap$769036610
P/E Ratio—
52W High$16.105
52W Low$4.75
Icosavax, Inc. (ICVX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ICVX · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 14, 2023EPS Actual
-$0.44
Est. -$0.57 · +22.8%
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 14, 2023
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
ICVX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2024 | Apr 4, 2024 | -$0.54 | — | — | — | — | — |
| ▲ Q4 FY2023 | Nov 14, 2023 | -$0.57 | -$0.44 | +22.8% | — | — | — |
| ▲ Q3 FY2023 | Aug 14, 2023 | -$0.60 | -$0.59 | +1.7% | — | — | — |
| — Q2 FY2023 | May 10, 2023 | -$0.60 | -$0.60 | +0.0% | — | — | — |
| ▼ Q1 FY2023 | Mar 30, 2023 | -$0.58 | -$0.59 | -1.7% | — | — | — |
| ▲ Q4 FY2022 | Nov 14, 2022 | -$0.57 | -$0.55 | +3.5% | — | — | — |
| ▼ Q3 FY2022 | Aug 15, 2022 | -$0.55 | -$0.57 | -3.6% | — | $0.00B | — |
| ▼ Q2 FY2022 | May 16, 2022 | -$0.49 | -$0.60 | -22.4% | — | $0.00B | — |
Q2 FY2024
Apr 4, 2024
EPS Actual
—
EPS Est.
-$0.54
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 14, 2023Beat
EPS Actual
-$0.44
EPS Est.
-$0.57
EPS Surpr.
+22.8%
Revenue
—
Q3 FY2023
Aug 14, 2023Beat
EPS Actual
-$0.59
EPS Est.
-$0.60
EPS Surpr.
+1.7%
Revenue
—
Q2 FY2023
May 10, 2023
EPS Actual
-$0.60
EPS Est.
-$0.60
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2023
Mar 30, 2023Miss
EPS Actual
-$0.59
EPS Est.
-$0.58
EPS Surpr.
-1.7%
Revenue
—
Q4 FY2022
Nov 14, 2022Beat
EPS Actual
-$0.55
EPS Est.
-$0.57
EPS Surpr.
+3.5%
Revenue
—
Q3 FY2022
Aug 15, 2022Miss
EPS Actual
-$0.57
EPS Est.
-$0.55
EPS Surpr.
-3.6%
Revenue
—
Q2 FY2022
May 16, 2022Miss
EPS Actual
-$0.60
EPS Est.
-$0.49
EPS Surpr.
-22.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.62 | $1.54 | $1.49 | 0 |
| Q2 FY2024 | $1.41 | $1.34 | $1.30 | 0 |
| Q1 FY2024 | $1.66 | $1.58 | $1.52 | 1 |
| Q4 FY2023 | $-0.61 | $-0.58 | $-0.56 | 4 |
| Q3 FY2023 | $-0.60 | $-0.59 | $-0.54 | 4 |
| Q2 FY2023 | $-0.63 | $-0.60 | $-0.58 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 14, 2023 | +22.8% | $6.86 | $8.10 | +18.08% |
| ▲ Q3 FY2023 | Aug 14, 2023 | +1.7% | $7.77 | $7.76 | -0.13% |
| ▲ Q2 FY2023 | May 10, 2023 | +0.0% | $7.23 | $7.65 | +5.81% |
| ▼ Q1 FY2023 | Mar 30, 2023 | -1.7% | $6.33 | $5.62 | -11.22% |
| ▲ Q4 FY2022 | Nov 14, 2022 | +3.5% | $2.49 | $2.32 | -6.83% |
| ▼ Q3 FY2022 | Aug 15, 2022 | -3.6% | $8.98 | $9.21 | +2.56% |
| ▼ Q2 FY2022 | May 16, 2022 | -22.4% | $7.64 | $7.41 | -3.01% |
| ▼ Q1 FY2022 | Mar 30, 2022 | -9.5% | $5.43 | $5.33 | -1.84% |
Q4 FY2023+18.08%
Report Date
Nov 14, 2023
EPS Beat/Miss
+22.8%
Price Before
$6.86
Price After
$8.10
Q3 FY2023-0.13%
Report Date
Aug 14, 2023
EPS Beat/Miss
+1.7%
Price Before
$7.77
Price After
$7.76
Q2 FY2023+5.81%
Report Date
May 10, 2023
EPS Beat/Miss
+0.0%
Price Before
$7.23
Price After
$7.65
Q1 FY2023-11.22%
Report Date
Mar 30, 2023
EPS Beat/Miss
-1.7%
Price Before
$6.33
Price After
$5.62
Q4 FY2022-6.83%
Report Date
Nov 14, 2022
EPS Beat/Miss
+3.5%
Price Before
$2.49
Price After
$2.32
Q3 FY2022+2.56%
Report Date
Aug 15, 2022
EPS Beat/Miss
-3.6%
Price Before
$8.98
Price After
$9.21
Q2 FY2022-3.01%
Report Date
May 16, 2022
EPS Beat/Miss
-22.4%
Price Before
$7.64
Price After
$7.41
Q1 FY2022-1.84%
Report Date
Mar 30, 2022
EPS Beat/Miss
-9.5%
Price Before
$5.43
Price After
$5.33
Avg Beat Reaction+4.23%
Avg Miss Reaction-3.38%
Beat Rate4 / 8 quarters
Largest Move+18.08% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ICVX ends December
Icosavax, Inc. (ICVX) most recently reported earnings on November 14, 2023 for Q4 FY2023, posting EPS of $-0.44 — beating the analyst consensus of $-0.57 by +22.8%. ICVX has beaten EPS estimates for 3 consecutive quarters. The next ICVX earnings date is expected around September 1, 2026.
Each quarter, investors track ICVX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ICVX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ICVX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ICVX earnings · 5 questionsIcosavax, Inc.'s next earnings report is expected around September 1, 2026. ICVX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ICVX historically reports after market close (AMC).
ICVX earnings datewhen is ICVX earningsICVX next earnings datewhen does ICVX report earningsICVX earnings calendar
▸ Source: FMP · Icosavax, Inc. SEC filings · US GAAP · Icosavax, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026